anti-Cytochrome P450, Family 2, Subfamily C, Polypeptide 19 (CYP2C19) Antibodies

CYP2C19 encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP2C19 Kits (9) and CYP2C19 Proteins (3) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
CYP2C19 1557 P33261
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online

Top anti-CYP2C19 Antibodies at

Showing 10 out of 81 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Delivery Price Details
Cow Rabbit Un-conjugated WB WB Suggested Anti-CYP2C19 Antibody Titration:  0.2-1 ug/ml  ELISA Titer:  1:312500  Positive Control:  Human Placenta Host:  Rabbit  Target Name:  WT1  Sample Type:  721_B  Antibody Dilution:  1.0ug/ml  CYP2C19 is supported by BioGPS gene expression data to be expressed in 721_B 100 μL 2 to 3 Days
Human Rabbit Un-conjugated ELISA, WB Western blot analysis of extracts from 293 cells, using Cytochrome P450 2C19 Antibody. The lane on the right is treated with the synthesized peptide. 100 μg 2 to 3 Days
Human Rabbit Un-conjugated IC, IF, IHC, WB Immunofluorescent analysis of Cytochrome P450 2C19 staining in Hela cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a hidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue). Immunohistochemical analysis of Cytochrome P450 2C19 staining in human brain formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugad compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. 200 μL 13 to 14 Days
Human Rabbit Un-conjugated EIA, IHC (p), WB 0.4 mL 6 to 8 Days
Human Rabbit Un-conjugated ELISA, IF, IHC, WB Western Blot (WB) analysis of specific cells using CYP2C19 Polyclonal Antibody. 100 μL Available
Human Rabbit Un-conjugated IHC (p), WB   100 μg 4 to 6 Days
Cow Rabbit Un-conjugated WB 100 μL 11 to 14 Days
Human Rabbit Un-conjugated ELISA, ICC, IF, WB Western blot analysis on 293 cell lysate using Cytochrome P450 2C19 Antibody,The lane on the left is treated with the antigen-specific peptide. ABIN6266992 staining 293 cells by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100,then blocked in 10% serum for 45 minutes at 25°C. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37°C. An Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) antibody(Cat.# S0006), diluted at 1/600, was used as secondary antibody. 100 μL 11 to 12 Days
Human Rabbit Un-conjugated IHC (p), WB Western Blot at 1:2000 dilution + human liver lysate Lysates/proteins at 20 ug per lane. Western blot analysis of CYP2C19 Antibody in Jurkat cell line lysates (35ug/lane) 400 μL 2 to 3 Days
Human Rabbit Un-conjugated IF, IHC (p), WB Western Blot at 1:1000 dilution + human liver lysate Lysates/proteins at 20 ug per lane. Western blot analysis of CYP2C19 Antibody in HL-60 cell line lysates (35ug/lane) 400 μL 2 to 3 Days

Top referenced anti-CYP2C19 Antibodies

  1. Cow (Bovine) Polyclonal CYP2C19 Primary Antibody for WB - ABIN2777003 : Ji, Olson, Zhang, Hildebrandt, Wang, Ingle, Fredericksen, Sellers, Miller, Dixon, Brauch, Eichelbaum, Justenhoven, Hamann, Ko, Brüning, Chang-Claude, Wang-Gohrke, Schaid, Weinshilboum: Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. in Cancer research 2008 (PubMed)

More Antibodies against CYP2C19 Interaction Partners

Human Cytochrome P450, Family 2, Subfamily C, Polypeptide 19 (CYP2C19) interaction partners

  1. Iraqi Women with the GA genotype of rs4244285 in the cytochrome P450 family 2 subfamily C member 19 gene present a higher risk of breast cancer than the GG genotype and dominant models.

  2. A patient with a CYP2C19*3/*17 genotype presenting with a stent thrombosis after an uncomplicated index PCI procedure.

  3. CYP2C19 genotype does not impact clinical response to prasugrel or ticagrelor.

  4. Poor bioactivation of tamoxifen in patients with low CYP2D6 activity and high CYP2C19 metabolism represents a tamoxifen-treated patient group that has the worst clinical outcome.

  5. Among patients treated with clopidogrel, wearing a Cyp2C19 * 2 function loss allele didn't seem to be associated with a significantly higher risk of major cardiovascular events, nor a significantly lower risk of hemorragic complications.

  6. In healthy Chinese subjects, carriers of CYP2C19 loss-of-function allele(s) had significantly reduced exposure of clopidogrel active metabolite (CAM) and decreased levels of inhibition of platelet aggregation with clopidogrel; these genotypes therefore might be a determinant for the formation of CAM and its antiplatelet effects.

  7. allele frequency distributions for CYP2C19 and CYP2C9 variants among the Tunisian population are comparable to those among European and Middle Eastern populations; identified a common haplotype in the Tunisian population carrying the CYP2C19*17, CYP2C9*1 alleles, representing a haplotype encoding efficient metabolism of drugs that are substrates for CYP2C enzymes

  8. The platelet reactivity increased along with the number of loss of function (LOF) allele increased and did in order of haplotype*1, *2, and *3. This research suggested that LOF alleles and risk haplotypes in CYP2C19 could significantly attenuate the response to clopidogrel, which resulted in platelet aggregation.

  9. The adverse impact of CYP2C19*2 polymorphisms was found not only in the risk of the presence of coronary heart disease (CHD), but also in the adverse cardiovascular events in CHD patients during the follow-up period of 14 months.

  10. Polymorphism of the CYP2C19 gene may influence the effectiveness indices of Phenazepam therapy in patients with anxiety disorders comorbid with alcohol dependence.

  11. CYP2C19*2 polymorphism is not a risk factor for peptic ulcer in Polish population; the results suggested there is some interaction between gender, CYP2C19*2 polymorphism, and pathogenesis of H. pylori infection development

  12. The higher risk of major adverse cardiovascular or cerebrovascular associated with clopidogrel use in CYP2C19 LOF allele carriers suggests that use of genotype-guided DAPT in practice may improve clinical outcomes.

  13. The CYP2C19*2 allele is common in the Palestinian population and its reduced metabolic activity is associated with increased incidence of major cardiac events in patients receiving clopidogrel.

  14. Esomeprazole did not affect that of prasugrel irrespective of CYP2C19 genotype.

  15. The effect of CKD on CYP1A2, CYP2C9, and CYP2C19 was variable and modest compared to CYP2C8 and OATP.

  16. It was found that progesterone (P4) modulated the both kinetic and equilibrium constants of CYB5A/CYP17A1 and CYB5/CYP21A2 complex formation and complexes, while not affecting the CYB5A/CYP2C19 interaction.

  17. CYP2C19 polymorphism affects residual platelet reactivity during maintenance with prasugrel in Korean outpatients.

  18. The carriage of CYP2C19*2 or *3 mutant allele was significantly associated with attenuated platelet response to clopidogrel and increased clopidogrel resistance risk.

  19. These results highlight that CYP2C19*2, along with diabetes, and use of proton pump inhibitor and statin are important factors jointly associated with variability in clinical response to Dual antiplatelet therapy following acute coronary syndrome in Egyptians

  20. The CYP2C19 genotype had a substantial impact on exposure and therapeutic failure of escitalopram, as measured by switching of antidepressant therapy. The results support the potential clinical utility of CYP2C19 genotyping for individualization of escitalopram therapy.

CYP2C19 Antigen Profile

Protein Summary

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.

Gene names and symbols associated with CYP2C19

  • cytochrome P450 family 2 subfamily C member 19 (CYP2C19) antibody
  • cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) antibody
  • cytochrome P450 2C19 (CYP2C19) antibody
  • CPCJ antibody
  • CYP2C antibody
  • P450C2C antibody
  • P450IIC19 antibody

Protein level used designations for CYP2C19

(R)-limonene 6-monooxygenase , (S)-limonene 6-monooxygenase , (S)-limonene 7-monooxygenase , CYPIIC17 , CYPIIC19 , S-mephenytoin 4-hydroxylase , cytochrome P-450 II C , cytochrome P450 2C19 , cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19 , cytochrome P450-11A , cytochrome P450-254C , flavoprotein-linked monooxygenase , mephenytoin 4'-hydroxylase , mephenytoin 4-hydroxylase , microsomal monooxygenase , xenobiotic monooxygenase , cytochrome P450 2C

1557 Homo sapiens
510380 Bos taurus
100534653 Ovis aries
Selected quality suppliers for anti-CYP2C19 (CYP2C19) Antibodies
Did you look for something else?